FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129955913> ?p ?o ?g. }

• W2129955913 endingPage "e1001733" @default.
• W2129955913 startingPage "e1001733" @default.
• W2129955913 abstract "Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-negative women. Methods and Findings A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86–1.22; p = 0.80 in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737 [3.2%] in the MQ group; RR, 0.70 [95% CI 0.51–0.96]; p = 0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and 1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85–0.99]; p = 0.03), and reduced incidence of clinical malaria (96/551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95% CI 0.52–0.88]; p = 0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78–0.95]; p = 0.003). There were no differences in the prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5% after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2) with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly the safety assessment. Conclusions Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy. Trial registration ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343 Please see later in the article for the Editors' Summary" @default.
• W2129955913 created "2016-06-24" @default.
• W2129955913 creator A5003048627 @default.
• W2129955913 creator A5004215770 @default.
• W2129955913 creator A5005365222 @default.
• W2129955913 creator A5009319293 @default.
• W2129955913 creator A5012661526 @default.
• W2129955913 creator A5013340768 @default.
• W2129955913 creator A5015285519 @default.
• W2129955913 creator A5015436967 @default.
• W2129955913 creator A5022330980 @default.
• W2129955913 creator A5029955706 @default.
• W2129955913 creator A5034858433 @default.
• W2129955913 creator A5041912518 @default.
• W2129955913 creator A5043369631 @default.
• W2129955913 creator A5043650852 @default.
• W2129955913 creator A5044394452 @default.
• W2129955913 creator A5044589743 @default.
• W2129955913 creator A5048576638 @default.
• W2129955913 creator A5054166664 @default.
• W2129955913 creator A5058335415 @default.
• W2129955913 creator A5061858171 @default.
• W2129955913 creator A5063482324 @default.
• W2129955913 creator A5074442267 @default.
• W2129955913 creator A5075225504 @default.
• W2129955913 creator A5076206975 @default.
• W2129955913 creator A5079432553 @default.
• W2129955913 creator A5079955811 @default.
• W2129955913 creator A5080121371 @default.
• W2129955913 date "2014-09-23" @default.
• W2129955913 modified "2023-10-16" @default.
• W2129955913 title "Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial" @default.
• W2129955913 cites W1564391643 @default.
• W2129955913 cites W1760515944 @default.
• W2129955913 cites W1967079612 @default.
• W2129955913 cites W1967304327 @default.
• W2129955913 cites W1984937452 @default.
• W2129955913 cites W1987142506 @default.
• W2129955913 cites W1987836379 @default.
• W2129955913 cites W1993380206 @default.
• W2129955913 cites W1999420196 @default.
• W2129955913 cites W2003123290 @default.
• W2129955913 cites W2011899660 @default.
• W2129955913 cites W2012733980 @default.
• W2129955913 cites W2021704622 @default.
• W2129955913 cites W2033831018 @default.
• W2129955913 cites W2061985630 @default.
• W2129955913 cites W2076371361 @default.
• W2129955913 cites W2082964002 @default.
• W2129955913 cites W2092663462 @default.
• W2129955913 cites W2102280420 @default.
• W2129955913 cites W2106333752 @default.
• W2129955913 cites W2112669742 @default.
• W2129955913 cites W2113485405 @default.
• W2129955913 cites W2117494840 @default.
• W2129955913 cites W2123053573 @default.
• W2129955913 cites W2128779446 @default.
• W2129955913 cites W2129955913 @default.
• W2129955913 cites W2132238586 @default.
• W2129955913 cites W2134505418 @default.
• W2129955913 cites W2137359026 @default.
• W2129955913 cites W2138514282 @default.
• W2129955913 cites W2138692289 @default.
• W2129955913 cites W2144700918 @default.
• W2129955913 cites W2148165159 @default.
• W2129955913 cites W2152609980 @default.
• W2129955913 cites W2166068761 @default.
• W2129955913 cites W2166852124 @default.
• W2129955913 cites W2255581309 @default.
• W2129955913 cites W2310319955 @default.
• W2129955913 cites W2321169184 @default.
• W2129955913 cites W2396358117 @default.
• W2129955913 cites W2414725590 @default.
• W2129955913 cites W2977524263 @default.
• W2129955913 cites W4250572576 @default.
• W2129955913 doi "https://doi.org/10.1371/journal.pmed.1001733" @default.
• W2129955913 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4172436" @default.
• W2129955913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25247709" @default.
• W2129955913 hasPublicationYear "2014" @default.
• W2129955913 type Work @default.
• W2129955913 sameAs 2129955913 @default.
• W2129955913 citedByCount "108" @default.
• W2129955913 countsByYear W21299559132014 @default.
• W2129955913 countsByYear W21299559132015 @default.
• W2129955913 countsByYear W21299559132016 @default.
• W2129955913 countsByYear W21299559132017 @default.
• W2129955913 countsByYear W21299559132018 @default.
• W2129955913 countsByYear W21299559132019 @default.
• W2129955913 countsByYear W21299559132020 @default.
• W2129955913 countsByYear W21299559132021 @default.
• W2129955913 countsByYear W21299559132022 @default.
• W2129955913 countsByYear W21299559132023 @default.
• W2129955913 crossrefType "journal-article" @default.
• W2129955913 hasAuthorship W2129955913A5003048627 @default.
• W2129955913 hasAuthorship W2129955913A5004215770 @default.
• W2129955913 hasAuthorship W2129955913A5005365222 @default.
• W2129955913 hasAuthorship W2129955913A5009319293 @default.
• W2129955913 hasAuthorship W2129955913A5012661526 @default.

• next